Day: May 13, 2022

POINT’s manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada for Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) targeted program. Trial is expected to commence this summer. INDIANAPOLIS, May 13, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the first quarter ended March 31, 2022 and provided a business update. “There were two very significant milestones for POINT in the first quarter of 2022,” said Dr. Joe McCann, CEO...

MAURITIUS, May 13, 2022 (GLOBE NEWSWIRE) — Alphamin Resources Corp. (AFM:TSXV, APH:JSE AltX)( “Alphamin” or the “Company”), a producer of 4% of the world’s mined tin1 from its high grade operation in the Democratic Republic of Congo, is pleased to provide the following operational update for the quarter ended March 2022:Q1 EBITDA2 of US$98.1m, up 32% from prior quarter Contained tin sold up 9% from the prior quarter to 3,336 tonnes Record plant recovery of 78% achieved (previous quarter: 75%) Net cash2 position increased 90% to US$129.8m, after a US$30m dividend payment Maiden mineral resource declared and subsequently updated at Mpama South Decision to commence construction of the Mpama South mine following positive PEA results Continued high grade assay results from ongoing drilling campaigns at Mpama North and Mpama SouthOperational...

Iceland Seafood will publish its Interim Financial Statement for Q1 2022 after closing of markets on May 17th 2022. The same day at 4.15pm, the company will host a meeting for investors and market participants, where management will present and discuss the results. The meeting will be held at the company‘s premises at Köllunarklettsvegur 2, 104 Reykjavík. The meeting will also be webcasted live in Icelandic, a link to the webcast and investor presentation will be provided before the meeting commence.  Participants to the online meeting can send questions in writing prior and during the meeting to the email investors@icelandseafood.com.

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) submitted to U.S. Food and Drug Administration (FDA); PDUFA date expected to be announced in June 2022Advancing ONS-5010 toward potential marketing approval in early 2023U.S. pre-launch commercial planning continues to ramp upOperations supported by access to funding expected to be sufficient to launch LYTENAVA, if approvedISELIN, N.J., May 13, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal second quarter ended March 31, 2022. Recent Corporate HighlightsSuccessfully submitted a BLA...

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its first quarter ended March 31, 2022. The Company ended the quarter with approximately $247 million in cash and cash equivalents. Pyxis Oncology remains on target to file INDs for anti-EDB, PYX-201, and anti-Siglec-15, PYX-106, in the second half of 2022 and INDs for anti-CD123, PYX-203, and anti-KLRG1, PYX-102, in the second half of 2023. Further, as previously disclosed, the Company expects to provide an update on its anti-DLK1 ADC, PYX-202, in mid-2022. Financial UpdateAs of May 13, 2022, Pyxis Oncology had cash and cash equivalents of approximately $231 million (preliminary, unaudited),...

First quarter 2022 consolidated revenue of $29.0 million up 60% from the same year ago period. Adjusted EPS of $(0.25), 14% sequential improvement versus the prior quarter. Re-affirm Full Year Adjusted EBITDA guidance and remain on track to reach Consolidated Adjusted EBITDA profitability by fourth quarter 2022. Cash balance of $25.1 million as of March 31, 2022 with no debt. Cash Flow during the quarter included $7 million of one-time cash outflows related to two acquisitions and related working capital investments.NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the first quarter ended March 31, 2022. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today, May 13,...

Expands rare cannabinoid portfolio with the addition of CBT and CBDV Strengthens IP with publication of a patent application for novel cannabinoid analogs Advances the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseasesVANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced financial results for the third quarter of the fiscal year 2022 which ended March 31, 2022. “The third quarter of fiscal 2022 saw noticeable advancements across all of our programs, including commencing sales of the rare cannabinoids CBDV and CBT as raw ingredients for the health and wellness industry,” says...

TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) today announces its financial results for the first quarter ending March 31, 2022 and provides an update on the Company’s activities at the Valentine Gold Project (the “Project”) in the central region of Newfoundland and Labrador (“NL”). First Quarter HighlightsAt March 31, 2022 the Company had cash and cash equivalents of $72.4 million, leaving it well positioned to execute on its permitting, development, and exploration activities at the Project; On March 31, 2022, the Company closed a US$185 million term loan credit facility with Sprott Private Resource Lending II (Collector-2) LP for the construction, development and working capital requirements of the Project; On March 17, 2022, the Company was notified that the Newfoundland...

TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced its financial results for the first quarter ended March 31, 2022 and provided a corporate update. Chris Seto, CEO of Spectral Medical, commented, “We are pleased to report continued progress on our Tigris trial. Specifically, enrollment activity ramped up following our February investigator meeting along with the recent protocol amendment acceptance by the FDA allowing for the use of SOFA scoring as inclusion criteria into the study. We have now randomized...